The Untapped Frontier: Digital Therapeutics & Pharma’s Commercial Imperative

The Centers for Medicare & Medicaid Services (CMS) 2024 Proposed Rule for Medicare Physician Fee Schedule (MPFS) introduced a game-changing clarity around remote therapeutic monitoring (RTM) and, by extension, the broader digital therapeutics (DTx) landscape. While not directly addressing DTx reimbursement, the rule signaled a pivotal shift in how the largest U.S. payer views digitally-enabled care. It laid a foundational — if still nascent — framework for how digital health interventions can generate billable services, which in turn offers a tangible pathway for pharma to integrate and co-market DTx solutions. This isn't just about codes, it's about legitimizing a new class of intervention within the highly scrutinized U.S. healthcare system, directly impacting the commercial calculus for pharmaceutical companies eyeing this space. For pharma marketers, biotech commercial leaders, and market access teams, understanding this subtle but profound regulatory pulse is paramount. It dictates not only what is technically possible but, more critically, what is commercially viable in the evolving synergy between traditional pharmaceuticals and cutting-edge digital health.

The promise of Digital Therapeutics (DTx) — software-driven interventions delivering evidence-based therapeutic outcomes — has long tantalized the pharmaceutical industry. The allure is clear: enhanced patient outcomes, improved adherence, real-world data generation, and novel revenue streams. Yet, the path to mainstream adoption, particularly within pharma's highly regulated and risk-averse commercial ecosystem, remains complex. Co-marketing models represent the most immediate and impactful bridge, but their success hinges on navigating a labyrinth of regulatory clarity (or lack thereof), payer appetite, and internal strategic alignment. The challenge is not merely technological, it is fundamentally a commercial and market access one, requiring a departure from pharma’s traditional playbook.

Defining the Landscape: Why Co-Marketing is the Go-To Strategy

Pharma’s inherent strengths lie in clinical development, regulatory navigation, and established physician relationships. DTx companies, conversely, excel in agile software development, user experience design, and data analytics. A strategic co-marketing partnership leverages these complementary strengths, accelerating market penetration and maximizing value creation for both parties. Without such collaboration, DTx companies struggle with market access and physician adoption at scale, while pharma risks being left behind in a rapidly digitalizing healthcare environment. It’s a symbiotic relationship, increasingly essential as healthcare shifts towards value-based care and personalized medicine.

The alternative for pharma – building DTx capabilities from scratch – is often prohibitively slow, expensive, and culturally misaligned. Acquisitions, while possible, come with integration complexities and the risk of stifling the very innovation they sought to acquire. Co-marketing,, becomes the pragmatic, capital-efficient, and often faster route to market, allowing pharma to test the waters, learn, and iterate without betting the entire farm.

The Evolving Regulatory & Reimbursement Terrain for DTx

The FDA has been a relatively progressive actor, establishing pathways like 510(k) and De Novo classifications for DTx, culminating in notable approvals such as Pear Therapeutics' reSET® for substance use disorder (2017) and reSET-O® for opioid use disorder (2018) – though Pear’s subsequent market challenges underscore the reimbursement hurdle. CMS’s RTM codes (98975, 98976, 98977, 98980, 98981) for 2022 and 2023, while not specifically for DTx, created a mechanism for clinicians to bill for time spent monitoring patients using digital tools, blurring the lines and opening doors. Private payers are slowly following suit, but coverage remains fragmented and often dependent on robust clinical evidence specific to the DTx and disease state.

This dynamic regulatory landscape impacts co-marketing strategies profoundly. A DTx with robust FDA clearance and established reimbursement pathways (e.g., through specific CPT codes or inclusion in payer formularies) offers a much clearer commercial narrative for pharma. Conversely, a DTx still navigating regulatory hurdles or lacking clear reimbursement requires a co-marketing model focused more on evidence generation and market shaping.

Strategic Co-Marketing Models: A Deeper Dive

The collaboration between pharma and DTx companies isn't monolithic. Several distinct models have emerged, each with its own benefits, risks, and strategic implications.

1. The “Enhancement” Model: DTx as a Companion Tool

Description: Here, the DTx acts as a companion to a specific pharmaceutical product, enhancing its value proposition. This might involve improving adherence, providing personalized patient education, managing side effects, or collecting real-world data to demonstrate drug effectiveness. The DTx is often prescribed alongside or integrated with the drug. A prime example is the collaboration between Propeller Health and multiple pharma companies to integrate its sensor-based inhaler technology with existing respiratory medications, providing insights into medication use and symptom triggers.

Strategic Value: This model directly addresses common pharma challenges: patient adherence (a notorious issue across therapeutic areas, leading to suboptimal outcomes and lost revenue), differentiation in crowded markets, and post-market surveillance. It can extend the life cycle of existing drugs or provide a competitive edge for new launches. The value proposition is often tied to the drug's performance and patient outcomes.

Commercial & Regulatory Considerations: Promotional messaging must clearly differentiate between the drug and the DTx, especially if the DTx has its own regulatory clearance. Pricing and reimbursement for the DTx may be separate from the drug or bundled, requiring intricate market access strategies. The data generated by the DTx can also be used to support real-world evidence claims for the drug, provided appropriate data governance and privacy protocols are in place. Legal teams must carefully review claims to avoid off-label promotion.

2. The “Stand-Alone Referral” Model: DTx as a Prescription Therapy

Description: In this model, the DTx is marketed and prescribed as an independent therapy for a specific condition, potentially in parallel with or instead of a drug. Pharma's role shifts from promoting its own drug to promoting the DTx as a valuable treatment option within a disease area of shared interest. Companies like Otsuka, through its partnership with Proteus Digital Health (though Proteus faced commercial hurdles), explored co-marketing an ingestible sensor paired with an antipsychotic. While that specific venture encountered challenges, the underlying model of DTx as a distinct, physician-prescribed intervention remains relevant.

Strategic Value: This positions pharma as a holistic solution provider in a therapeutic area, moving beyond molecules to integrated care. It allows pharma to enter new segments of a market or address unmet needs where drug therapy alone is insufficient. It diversifies revenue streams and provides market intelligence on a broader patient population.

Commercial & Regulatory Considerations: This model demands robust DTx-specific evidence (e.g., randomized controlled trials demonstrating clinical efficacy) to secure payer coverage and physician adoption. Pharma's marketing efforts must focus on educating prescribers on the DTx's clinical benefits, mechanism of action, and patient selection criteria, much like launching a new drug. Reimbursement pathways are critical and may involve working with private payers and navigating emerging CMS guidance.

3. The “Data & Insights” Model: DTx for Market Intelligence & R&D

Description: Less about direct patient-facing commercialization, this model focuses on using DTx platforms to gather real-world data, patient insights, and disease progression patterns. This data can inform R&D, clinical trial design, biomarker discovery, and population health strategies. Sanofi's multi-year collaboration with Evidation Health to collect real-world data across various therapeutic areas (e.g., diabetes, cardiovascular disease) exemplifies this approach.

Strategic Value: Provides pharma with a competitive edge in understanding disease progression, treatment response, and unmet patient needs. It can de-risk R&D investments, identify new indications, or optimize treatment algorithms. The value is long-term and strategic, not directly linked to immediate product sales.

Commercial & Regulatory Considerations: Primary considerations involve data privacy (HIPAA, GDPR), data security, and ethical data use. Co-marketing efforts are generally B2B, targeting R&D, medical affairs, and market access teams, rather than physicians or patients directly. The DTx company's expertise in data analytics and privacy-by-design principles becomes paramount.

4. The “Hybrid Ecosystem” Model: Integrated Patient Journey

Description: This represents a more advanced and integrated approach, where the pharma company and DTx partner create a comprehensive ecosystem that supports the entire patient journey – from diagnosis and treatment initiation to ongoing management and outcomes monitoring. It combines elements of enhancement, stand-alone therapy, and data collection. Eli Lilly's multi-faceted collaborations in diabetes, including with continuous glucose monitoring (CGM) companies and digital health platforms, illustrate the ambition to create such integrated patient support systems.

Strategic Value: Offers maximum value by creating a differentiated, sticky patient experience. Positions pharma as a true partner in patient care, enhancing brand loyalty and market leadership. Drives better health outcomes and potentially opens pathways for value-based contracting.

Commercial & Regulatory Considerations: This is the most complex model, requiring deep integration across technology, commercial, medical, and market access functions. It necessitates clear ownership, revenue sharing models, and a harmonized regulatory strategy for all components. Compliance with a multitude of healthcare regulations is critical, as is ensuring a seamless user experience across multiple touchpoints.

Overcoming Commercialization Hurdles: A Pharma Imperative

Even with clear co-marketing models, pharma faces significant commercialization hurdles unique to DTx.

Payer Engagement & Reimbursement Strategy

Payer coverage for DTx remains highly variable. Pharma must advocate for DTx inclusion in formularies, negotiate value-based agreements, and provide robust health economic outcomes research (HEOR) data. This requires a shift from drug-centric HEOR to demonstrating the DTx's impact on total cost of care, hospitalization rates, and quality of life metrics. Engaging payers early, even during DTx development, is crucial to align on evidence requirements.

Physician Education & Workflow Integration

Prescribers often lack awareness or understanding of DTx. Pharma’s sales forces, traditionally trained on molecules, need extensive education on the DTx's clinical application, patient selection, and practical integration into clinical workflow. The DTx must be easy to prescribe, onboard patients, and monitor effectively, without adding significant burden to already strained healthcare providers.

Patient Adoption & Adherence

Patients, even with a prescription, may not download, activate, or consistently use a DTx. Pharma must contribute to patient education campaigns, provide clear onboarding support, and understand user experience factors that drive engagement. The DTx company's expertise in behavioral science and user interface design becomes a critical component of the joint commercial strategy.

Data Governance & Interoperability

The wealth of data generated by DTx is a double-edged sword. While invaluable for insights, it necessitates stringent data governance, privacy compliance, and robust cybersecurity. Interoperability with electronic health records (EHRs) is a persistent challenge but essential for seamless clinical integration and data flow.

The Path Forward: Vision for a Blended Future

The future of pharma marketing increasingly involves a blended approach where molecules and digital solutions are inextricably linked. The success of co-marketing DTx hinges on strategic foresight, a willingness to adapt traditional commercial models, and a deep understanding of the regulatory, payer, and clinical realities. For U.S. pharma marketers and their partners, this means moving beyond product-centric thinking towards a patient-centric, ecosystem-driven strategy.

To thrive, pharma must:

  • Invest in specialized talent: Build or acquire teams with expertise in digital health, behavioral science, user experience, and novel market access strategies for digital products.
  • Prioritize evidence generation: Fund and support robust clinical trials and real-world studies that demonstrate the DTx’s clinical and economic value, tailor-made for payer needs.
  • Embrace agility: Adopt more iterative, software-development-like approaches to product launch, marketing, and post-market adaptation.
  • Forge authentic partnerships: Select DTx partners based on strong scientific evidence, robust technology, and cultural alignment, fostering genuine collaboration rather than transactional relationships.

The 2024 CMS proposals, while modest in scope, represent a fundamental shift. They hint at a healthcare system increasingly ready to recognize and reimburse digital interventions. For pharma, this isn't just an opportunity, it's an evolutionary imperative to secure relevance and leadership in the next era of healthcare delivery.

References & Sources

1. Centers for Medicare & Medicaid Services. (2023). Medicare Program, CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies. Federal Register. https://www.federalregister.gov/documents/2023/11/16/2023-24169/medicare-program-cy-2024-payment-policies-under-the-physician-fee-schedule-and-other-changes-to-part

2. Digital Therapeutics Alliance. (Ongoing). DTx Product Library & Market Access Resources. https://dtxalliance.org/dtx-products/

3. FDA. (Ongoing). Digital Health Policies and Regulatory Guidance. https://www.fda.gov/medical-devices/digital-health-center-excellence/digital-health-policies-and-regulatory-guidance

4. Evidation Health. (2020). Sanofi and Evidation Health Collaborate to Better Understand Impact of Health Interventions on Everyday Health. https://www.evidation.com/news/sanofi-and-evidation-health-collaborate-to-better-understand-impact-of-health-interventions-on-everyday-health

5. Propeller Health. (Ongoing). Respiratory Care Solutions & Pharma Partnerships. https://www.propellerhealth.com/partners/

6. Proteus Digital Health. (Archived News). Otsuka and Proteus Digital Health Announce Abilify MyCite Launch. (Note: Proteus filed for bankruptcy in 2019, but its partnership with Otsuka was a landmark example of the model).

7. Eli Lilly and Company Investor Relations. (Various reports & presentations). Updates on diabetes care strategy and digital health initiatives.